Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice

Neurochemistry International

Volumn 55, Issue 8, 2009, Pages 760-767

  Inden, Masatoshi ^a   Kitamura, Yoshihisa ^a   Tamaki, Aya ^a   Yanagida, Takashi ^a   Shibaike, Tomonori ^a   Yamamoto, Atsuko ^a   Takata, Kazuyuki ^a   Yasui, Hiroyuki ^a   Taira, Takahiro ^b   Ariga, Hiroyoshi ^c   Taniguchi, Takashi ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Synuclein; DJ 1; Parkinson's disease; Pramipexole; Rotenone

Indexed keywords

ALPHA SYNUCLEIN; CYTOCHROME C; HYDROGEN PEROXIDE; PRAMIPEXOLE; PROTEIN BCL 2; ROTENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; MOTOR DYSFUNCTION; MOUSE; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAROD TEST; STRIATONIGRAL DEGENERATION; UPREGULATION;

ALPHA-SYNUCLEIN; ANIMALS; ANTIPARKINSON AGENTS; APOPTOSIS; BENZOTHIAZOLES; CELL LINE, TUMOR; CORPUS STRIATUM; CYTOCHROMES C; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN PEROXIDE; HYDROXYL RADICAL; MALE; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEURAL PATHWAYS; NEUROTOXINS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; PROTO-ONCOGENE PROTEINS C-BCL-2; ROTENONE; SUBSTANTIA NIGRA; UNCOUPLING AGENTS;

MUS;

EID: 70349970004     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.07.009     Document Type: Article

References (45)

1. Barone P. Clinical strategies to prevent and delay motor complications. Neurology 61 (2003) S12-S16
2. Bashkatova V., Alam M., Vanin A., and Schmidt W.J. Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain. Exp. Neurol. 186 (2004) 235-241
3. Betarbet R., Sherer T.B., Mackenzie G., Garcia-Osuna M., Panov A.V., and Geenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
4. Bouchez G., Sensebé L., Vourc'h P., Garreau L., Bodard S., Rico A., Guilloteau D., Charbord P., Besnard J.C., and Chalon S. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Neurochem. Int. 52 (2008) 1332-1342
5. +, or paraquat. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 15136-15141
6. Clarke C.E., and Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 360 (2002) 1767-1769
7. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., and Kopin I.J. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1 (1979) 249-254
8. Dunnett S.B., and Björklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399 Suppl. (1999) A32-A39
9. Ferger B., Teismann P., and Mierau J. The dopamine agonist pramipexole scavenges hydroxy free radicals induced by striatal application of 6-hydroxydopamine in rats: in vivo microdialysis study. Brain Res. 883 (2000) 216-223
10. 2-induced PC12 cell death. Naunyn Schmiedeberg's Arch. Pharmacol. 372 (2006) 257-266
11. Gu M., Iravani M.M., Cooper J.M., King D., Jenner P., and Schapira A.H. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 91 (2004) 1075-1081
12. Hall E.D., Andrus P.K., Oostveen J.A., Althaus J.S., and Vonvoigtlander P.F. Neuroprotective effects of the dopamine D2/3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 742 (1996) 80-88
13. Höglinger G.U., Féger J., Prigent A., Michel P.P., Parain K., Champy P., Ruberg M., Oertel W.H., and Hirsch E.C. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84 (2003) 491-502
14. Höglinger G.U., Lannuzel A., Khondiker M.E., Michel P.P., Duyckaerts C., Féger J., Champy P., Prigent A., Medja F., Lombes A., Oertel W.H., Ruberg M., and Hirsch E.C. The mitochondrial complex I inhibitor rotenone triggers a cerebral taupathy. J. Neurochem. 95 (2005) 930-939
15. Inden M., Kitamura Y., Takeuchi H., Yanagida T., Takata K., Kobayashi Y., Taniguchi T., Yoshimoto K., Kaneko M., Okuma Y., Taira T., Ariga H., and Shimohama S. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J. Neurochem. 101 (2007) 1491-1504
16. Iravani M.M., Haddon C.O., Cooper J.M., Jenner P., and Schapira A.H. Pramipexole protects against MPTP toxicity in non-human primates. J. Neurochem. 96 (2006) 1315-1321
17. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A., Kittel A., and Saitoh T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14 (1995) 467-475
18. Izumi Y., Sawada H., Yamamoto N., Kume T., Katsuki H., Shimohama S., and Akaike A. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Eur. J. Pharmacol. 557 (2007) 132-140
19. Kakimura J., Kitamura Y., Takata K., Kohno Y., Nomura Y., and Taniguchi T. Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol. 417 (2001) 59-67
20. Kitamura Y., Kohno Y., Nakazawa M., and Nomura Y. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice. Jpn. J. Pharmacol. 74 (1997) 51-57
21. Kitamura Y., Kosaka T., Kakimura J.I., Matsuoka Y., Kohno Y., Nomura Y., and Taniguchi T. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 54 (1998) 1046-1054
22. Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J.T., Schöls L., and Riess O. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
23. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
24. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., and Lansbury Jr. P.T. α-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322 (2002) 1089-1102
25. Lee H.J., Khoshaghideh F., Patel S., and Lee S.J. Clearance of a-synuclein oligomeric intermediates via the lysosomal degradation pathway. J. Neurosci. 24 (2004) 1888-1896
26. Li N., Ragheb K., Lawler G., Sturgis J., Rajwa B., Melendez J.A., and Robinson J.P. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem. 278 (2003) 8516-8525
27. 2 upon chronic rotenone treatment. Free Radic. Biol. Med. 39 (2005) 133-142
28. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
29. Ren Y., Liu W., Jiang H., Jiang Q., and Feng J. Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J. Biol. Chem. 280 (2005) 34105-34112
30. Saravanan K.S., Sindhu K.M., and Mohanakumar K.P. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res. 1049 (2005) 147-155
31. Saravanan K.S., Sindhu K.M., Senthilkumar K.S., and Mohanakumar K.P. l-Deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats. Neurochem. Int. 49 (2006) 28-40
32. Schapira A. Etiology of Parkinson's disease. Neurology 66 (2006) S10-S23
33. Setsuie R., and Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem. Int. 51 (2007) 105-111
34. Sherer T.B., Kim J.H., Betarbet R., and Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation. Exp. Neurol. 179 (2003) 9-16
35. ATP channels. Neurochem. Int. 52 (2008) 80-88
36. Taira T., Saito Y., Niki T., Iguchi-Ariga S.M.M., Takahashi K., and Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 5 (2004) 213-218
37. Takahashi-Niki K., Niki T., Taira T., Iguchi-Ariga S.M.M., and Ariga H. Reduced anti-oxidative stress activities of DJ-1 mutants found in Parkinson's disease patients. Biochem. Biophys. Res. Commun. 320 (2004) 389-397
38. Takata K., Kitamura Y., Kakimura J., Kohno Y., and Taniguchi T. Increase of Bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole. Brain Res. 872 (2000) 236-241
39. Takeuchi H., Yanagida T., Inden M., Takata K., Kitamura Y., Yamakawa K., Sawada H., Izumi Y., Yamamoto N., Kihara T., Uemura K., Inoue H., Tanigichi T., Akaike A., Takahashi R., and Shimohama S. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models. J. Neurosci. Res. 87 (2009) 576-585
40. Testa C.M., Sherer T.B., and Greenamyre J.T. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain. Res. Mol. Brain. Res. 134 (2005) 109-118
41. Tintner R., and Jankovic J. Dopamine agonists in Parkinson's disease. Expert Opin. Investig. Drugs 12 (2003) 1803-1820
42. Tsigelny I.F., Bar-On P., Sharikov Y., Crews L., Hashimoto M., Miller M.A., Keller S.H., Platoshyn O., Yuan J.X., and Masliah E. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by β-synuclein. FEBS J. 274 (2007) 1862-1877
43. Uversky V.N., Lee H.J., Li J., Fink A.L., and Lee S.J. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J. Biol. Chem. 276 (2001) 43495-43498
44. Walsh D.M., and Selkoe D.J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. 11 (2004) 213-228
45. Yanagisawa D., Kitamura Y., Inden M., Takata T., Taniguchi T., Morikawa S., Morira M., Inubushi T., Tooyama I., Taira T., Iguchi-Ariga S.M.M., Akaike A., and Ariga H. DJ-1 protects against neurodegeneration caused by focal cerebral ischemia and reperfusion in rats. J. Cereb. Blood Flow Metab. 28 (2008) 563-578